These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 11521772)
81. Inferring speaker attributes in adductor spasmodic dysphonia: ratings from unfamiliar listeners. Isetti D; Xuereb L; Eadie TL Am J Speech Lang Pathol; 2014 May; 23(2):134-45. PubMed ID: 24686338 [TBL] [Abstract][Full Text] [Related]
82. Teaching video NeuroImage: Spasmodic dysphonia: adductor and abductor. Reich SG; Meyer T Neurology; 2008 May; 70(19):e78. PubMed ID: 18458222 [No Abstract] [Full Text] [Related]
83. Liquid-type Botulinum Toxin Type A in Adductor Spasmodic Dysphonia: A Prospective Pilot Study. Cha W; Jang JY; Wang SG; Kang JH; Jo MG J Voice; 2017 May; 31(3):378.e19-378.e24. PubMed ID: 27520509 [TBL] [Abstract][Full Text] [Related]
84. Treatment of adductor-type spasmodic dysphonia by surgical myectomy: a preliminary report. Koufman JA; Rees CJ; Halum SL; Blalock D Ann Otol Rhinol Laryngol; 2006 Feb; 115(2):97-102. PubMed ID: 16514790 [TBL] [Abstract][Full Text] [Related]
85. Long-term voice handicap index after type II thyroplasty using titanium bridges for adductor spasmodic dysphonia. Sanuki T; Yumoto E; Kodama N; Minoda R; Kumai Y Auris Nasus Larynx; 2014 Jun; 41(3):285-9. PubMed ID: 24369905 [TBL] [Abstract][Full Text] [Related]
86. A comparison of the VHI, VHI-10, and V-RQOL for measuring the effect of botox therapy in adductor spasmodic dysphonia. Morzaria S; Damrose EJ J Voice; 2012 May; 26(3):378-80. PubMed ID: 20951552 [TBL] [Abstract][Full Text] [Related]
88. Unilateral versus bilateral botulinum toxin injections in spasmodic dysphonia: acoustic and perceptual results. Adams SG; Hunt EJ; Charles DA; Lang AE J Otolaryngol; 1993 Jun; 22(3):171-5. PubMed ID: 8371328 [TBL] [Abstract][Full Text] [Related]
89. Judgment of voice improvement after recurrent laryngeal nerve section for spastic dysphonia: clinicians versus patients. Sapir S; Aronson AE; Thomas JE Ann Otol Rhinol Laryngol; 1986; 95(2 Pt 1):137-41. PubMed ID: 3516048 [TBL] [Abstract][Full Text] [Related]
90. Effects of botulinum toxin on pathophysiology in spasmodic dysphonia. Bielamowicz S; Ludlow CL Ann Otol Rhinol Laryngol; 2000 Feb; 109(2):194-203. PubMed ID: 10685573 [TBL] [Abstract][Full Text] [Related]
91. [Abnormal adductor movement of the vocal cords in spasmodic dysphonia]. Shibusawa M Nihon Jibiinkoka Gakkai Kaiho; 1993 Apr; 96(4):659-64. PubMed ID: 8509938 [TBL] [Abstract][Full Text] [Related]
92. Evaluation of voice quality in adductor spasmodic dysphonia before and after botulinum toxin treatment. Langeveld TP; van Rossum M; Houtman EH; Zwinderman AH; Briaire JJ; Baatenburg de Jong RJ Ann Otol Rhinol Laryngol; 2001 Jul; 110(7 Pt 1):627-34. PubMed ID: 11465821 [TBL] [Abstract][Full Text] [Related]
93. Partial thyroarytenoid myectomy: an animal study investigating a proposed new treatment for adductor spasmodic dysphonia. Genack SH; Woo P; Colton RH; Goyette D Otolaryngol Head Neck Surg; 1993 Mar; 108(3):256-64. PubMed ID: 8464639 [TBL] [Abstract][Full Text] [Related]
94. Differential diagnosis of muscle tension dysphonia and adductor spasmodic dysphonia using spectral moments of the long-term average spectrum. Houtz DR; Roy N; Merrill RM; Smith ME Laryngoscope; 2010 Apr; 120(4):749-57. PubMed ID: 20222024 [TBL] [Abstract][Full Text] [Related]